GlassScriptPhysician profile
Allen Jacob
NPI 1982231015
$4,741.04
in general payments reported to CMS, 2019-2025
23 companies · $774 in 2025
The $774 reported for 2025 was more than what 81% of Internal Medicine providers received nationally (typical 2025 total: $156).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2023: $24.30 · 2024: $3,943 · 2025: $774.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Compensation For Services Other Than Consulting, Including Serving As Faculty Or As A Speaker At A Venue Other Than A Continuing Education Program: $2,750 · Food and Beverage: $1,895 · Education: $95.95.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Compensation For Services Other Than Consulting, Including Serving As Faculty Or As A Speaker At A Venue Other Than A Continuing Education Program | $2,750.00 |
| Food and Beverage | $1,895.09 |
| Education | $95.95 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Beigene USA, INC. | $2,750.00 | 2024 | Brukinsa |
| Incyte Corporation | $421.40 | 2024-2025 | Jakafi, Monjuvi, Niktimvo |
| Janssen Biotech, INC. | $382.79 | 2024-2025 | Tecvayli, Darzalex, Talvey |
| Merck Sharp & Dohme LLC | $169.26 | 2024-2025 | Keytruda, Welireg, Reblozyl |
| Regeneron Healthcare Solutions, INC. | $115.62 | 2024-2025 | Libtayo |
| Genmab U.S., INC. | $105.59 | 2024-2025 | Epkinly |
| Servier Pharmaceuticals LLC | $89.96 | 2024 | |
| Kite Pharma, INC. | $86.42 | 2024-2025 | Yescarta |
| Adc Therapeutics America, INC. | $70.69 | 2024 | |
| Syndax Pharmaceuticals, INC. | $66.08 | 2025 | |
| Glaxosmithkline, LLC. | $64.98 | 2023-2025 | Blenrep, Shingrix, Zejula |
| Karyopharm Therapeutics INC. | $64.34 | 2024-2025 | Xpovio |
| Geron Corporation | $49.90 | 2025 | Rytelo |
| Genzyme Corporation | $46.16 | 2024 | |
| Exelixis INC. | $45.78 | 2025 | Cabometyx |
Show all 23 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Rigel Pharmaceuticals, INC. | $38.32 | 2024-2025 | Rezlidhia, Tavalisse, Gavreto |
| Legend Biotech USA INC. | $27.93 | 2025 | Carvykti |
| Blueprint Medicines Corporation | $27.78 | 2024 | Ayvakit |
| Astrazeneca Pharmaceuticals LP | $27.70 | 2024 | Lynparza |
| Sobi, INC | $27.69 | 2024 | |
| Bayer Healthcare Pharmaceuticals INC. | $24.97 | 2024 | |
| Menarini Silicon Biosystems, INC. | $19.28 | 2024 | |
| Mirati Therapeutics, INC. | $18.40 | 2024 | Krazati |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Allen Jacob listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.